Skip to main content


A study of different Donanemab (LY3002813) dosing regimens in adults with early Alzheimer's disease

Eli Lilly and Company

Information about the drug that will be tested in the study


The drug will be administered via an intravenous infusion (an injection into the vein).

Is the drug already on the market for another medical condition?


Will all participants receive the same drug?

Participants will be selected by chance to receive one dose of Donanemab (between 4 doses). Participants will receive placebo at certain intervals to preserve the blind (also called a dummy treatment which is an inactive substance identical in appearance to the drug being tested with no active therapeutic effect).

Information about participating in the trial

What are the researchers trying to find out?

The purpose of the study is to investigate the effect of different doses of Donanemab on the frequency and severity of ARIA-E (a type of side effect caused by amyloid-modifying therapies) in people with early symptomatic Alzheimer’s disease (prodromal and mild dementia due to Alzheimer’s disease).

How long will the treatment last?

The treatment lasts 90 days

The study will last approximately 91 weeks and include up to 26 visits.

What your involvement will entail?
  • During the study, participants will have to undergo brain scan (MRI, PET) to evaluate the side effects and the amyloid level in the brain
  • Complete some laboratory tests (i.e. blood tests).

Further information on the procedures, tests and number of visits can be obtained from the study team.

Who can participate in this study?

Who can participate in the study?

To take part in the study, participants must:

  • Be between 60 and 85 years old
  • Have a gradual and progressive change in memory function reported by the participant or study partner for ≥6 months
  • Have a score between 20-28 points in the MMSE test (a test about a range of everyday mental skills). This would suggest that the person has an impairment that is at a very mild stage
  • Have evidence of abnormal accumulation of amyloid in their brain (as per results of brain scans).
Who cannot participate in the study?

People cannot take part in the study if they have or have experienced:

  • Any evidence of a neurological or neurodegenerative condition other than Alzheimer’s disease that may affect cognition or ability to complete the study, such as other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy
  • A disease or medical condition that may interfere with the study assessments and will make the participant unsuitable for participation in or completion of the trial procedures (i.e. cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic diseases
  • Presence or history of malignant neoplams within the last 5 years
  • A life expectancy of above 24 months
  • Participants must not have contraindication to MRI or PET scans.

The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.

Information for your doctor

EU trial Number

2022-502268-18-00 identifier


Study contact information

Link to full text

The information contained in this document is based on information available on public registries (e.g. website) on May 2023.


Alzheimer Europe's Clinical Trials Watch database was developed as part of the 2018 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).

Alzheimer Europe gratefully acknowledges the support of its corporate sponsors for the update and maintenance of the database.